quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:29:45·36d
SECFiling
4D Molecular Therapeutics Inc. logo

SEC Form 10-K filed by 4D Molecular Therapeutics Inc.

FDMT· 4D Molecular Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • FDMT
    4D Molecular Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$33.00
  • Nov 7UpdateMorgan Stanley-
  • Jan 13UpdateBMO Capital Markets$15.00
  • Nov 21UpdateMorgan Stanley$8.00
  • Sep 23UpdateCantor Fitzgerald-
  • Apr 15UpdateBarclays$45.00

Related

  • PR6d
    4DMT Announces New Employment Inducement Grants
  • SEC16d
    Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
  • SEC24d
    4D Molecular Therapeutics Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER27d
    SEC Form 4 filed by Simms Christopher Paul
  • INSIDER27d
    SEC Form 4 filed by Kirn David
  • INSIDER27d
    SEC Form 4 filed by Bizily Scott
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
  • INSIDER30d
    SEC Form 4 filed by Gupta Ashoo
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022